Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel hepatitis C virus replicon inhibitors: synthesis and structure-activity relationships of fused pyrimidine derivatives.

Bioorganic & medicinal chemistry letters - 15 Mar 2012

Krueger A Chris, Madigan Darold L, Beno David W, Betebenner David A, Carrick Robert, Green Brian E, He Wenping, Liu Dachun, Maring Clarence J, McDaniel Keith F, Mo Hongmei, Molla Akhteruzzaman, Motter Christopher E, Pilot-Matias Tami J, Tufano Michael D, Kempf Dale J

Abstract excerpt

The synthesis of several pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine analogs is described with one such analog possessing subnanomolar potency in both genotype 1a and 1b cell culture HCV replicon assays.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Pyrimidines

Share to Replicon

Share to RNA, Viral

Share to Structure-Activity Relationship

Share to Virus Replication

Source

Identifiers

PMID: 22342631
DOI: 10.1016/j.bmcl.2012.01.096

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel hepatitis C virus replicon inhibitors: synthesis and structure-activity relationships of fused pyrimidine derivatives.PMID 22342631Read ↗

Benzimidazole-containing HCV NS5A inhibitors: effect of 4-substituted pyrrolidines in balancing genotype 1a and 1b potency.Semantic proximity Read ↗

Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b replicons.Semantic proximity Read ↗

Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530).Semantic proximity Read ↗

Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase.Semantic proximity Read ↗

Novel nucleoside analogues targeting HCV replication through an NS5A-dependent inhibition mechanism.Semantic proximity Read ↗

Bicyclic octahydrocyclohepta[b]pyrrol-4(1H)one derivatives as novel selective anti-hepatitis C virus agents.Semantic proximity Read ↗

Identification and biological evaluation of a series of 1H-benzo[de]isoquinoline-1,3(2H)-diones as hepatitis C virus NS5B polymerase inhibitors.Semantic proximity Read ↗

HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activity.Semantic proximity Read ↗

Discovery and Development of Hepatitis C Virus NS5A Replication Complex InhibitorsSemantic proximity Read ↗

Synthesis, biological evaluation and in silico modeling of novel pan-genotypic NS5A inhibitors.Semantic proximity Read ↗

Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 2: non-symmetric inhibitors with potent activity against genotype 1a and 1b.Semantic proximity Read ↗

Discovery and characterization of substituted diphenyl heterocyclic compounds as potent and selective inhibitors of hepatitis C virus replication.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.